This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...
- 2024 net product sales of $336.4 million - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in PSC expected to complete enrollment in second half ...
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today ...
Madrigal Pharmaceuticals provided an update on its financial performance, revealing preliminary fourth-quarter and full-year 2024 net sales for Rezdiffra™ (resmetirom) projected between $100 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results